JMP Securities Reiterates a Buy Rating on Taysha Gene Therapies (TSHA)

In a report released today, Silvan Tuerkcan from JMP Securities reiterated a Buy rating on Taysha Gene Therapies (TSHAResearch Report), with a price target of $38.00. The company’s shares closed last Thursday at $9.51.

According to TipRanks.com, Tuerkcan is a 4-star analyst with an average return of 15.7% and a 35.2% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Crispr Therapeutics AG, and Logicbio Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Taysha Gene Therapies with a $39.14 average price target.

See the top stocks recommended by analysts >>

Taysha Gene Therapies’ market cap is currently $384.7M and has a P/E ratio of -2.64.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TSHA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.

Read More on TSHA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed